{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-26-000016","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.464296+00:00","generated_at":"2026-05-14T21:40:43.375554+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prothena Q1 net income $32.7M on $50M milestone; raises cash guidance","bullets":["Net income of $32.7M ($0.60 diluted EPS) vs net loss of $60.2M ($1.12 loss) in Q1 2025.","Revenue $51.1M (vs $2.8M), primarily from $50M Novo Nordisk milestone for coramitug Phase 3 enrollment.","Updated FY2026 net cash used guidance to $18-23M (prior $50-55M); year-end cash ~$273M (midpoint), up $18M.","Initiated up to $100M share repurchase program; repurchased 788,990 shares for $7.3M through Q1.","PRX019 Phase 1 completed; potential $55M milestone if Bristol Myers Squibb advances by YE 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-26-000016","json":"https://secwatch.observer/filing/0001559053-26-000016.json","markdown":"https://secwatch.observer/filing/0001559053-26-000016.md","text":"https://secwatch.observer/filing/0001559053-26-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905326000016/0001559053-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905326000016/prta-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:40:43.375554+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"83a799ded3cc70ab03cdf681fc745cd63029d00b","claim":"PROTHENA CORP PUBLIC LTD CO reported financial results for first quarter of 2026.","evidence_excerpt":"On May 7, 2026, Prothena Corporation plc issued a press release announcing its financial results for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1559053/000155905326000016/0001559053-26-000016-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}